Sulfisoxazole Elicits Robust Antitumour Immune Response Along with Immune Checkpoint Therapy by Inhibiting Exosomal PD‐L1

Despite their potent antitumor activity, clinical application of immune checkpoint inhibitors has been significantly limited by their poor response rates (

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Advanced science 2022-02, Vol.9 (5), p.e2103245-n/a
Hauptverfasser:	Shin, Jung Min, Lee, Chan‐Hyeong, Son, Soyoung, Kim, Chan Ho, Lee, Jae Ah, Ko, Hyewon, Shin, Sol, Song, Seok Ho, Park, Seong‐Sik, Bae, Ju‐Hyun, Park, Ju‐Mi, Choe, Eun‐Ji, Baek, Moon‐Chang, Park, Jae Hyung
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies Apoptosis B7-H1 Antigen - antagonists & inhibitors Biological activity Biosynthesis Cancer therapies combination therapy Cytotoxicity exosomal PD‐L1 exosome Exosomes - drug effects Exosomes - immunology Humans Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use immune checkpoint therapy immune escape Immunity Immunotherapy Lymphocytes Mice Neoplasms - drug therapy Remission (Medicine) Standard deviation Sulfisoxazole - pharmacology Sulfisoxazole - therapeutic use tumor microenvironment Tumor Microenvironment - drug effects Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Despite their potent antitumor activity, clinical application of immune checkpoint inhibitors has been significantly limited by their poor response rates (
ISSN:	2198-3844 2198-3844
DOI:	10.1002/advs.202103245